[PRESS RELEASE – Dubai, UAE, April 28th, 2026]
Built on Symbiotic Core and integrated into Midas’ Open Liquidity Architecture, the new partnership introduces a capital-efficient RFQ settlement layer for tokenized assets: T+0 atomic settlement with no idle capital and no pre-funded inventory.
Many tokenized assets remain effectively illiquid. Traditional redemption processes can take 60 to 180 days or longer, leaving capital frozen between settlement events. While tokenization has improved access, reliable, deep liquidity at scale is still an unresolved challenge.
Symbiotic and Midas today revealed the Instant Liquidity product for tokenized assets, built on Symbiotic Core V2. Symbiotic Instant Liquidity is an RFQ-based liquidity solution integrated into Midas’ Open Liquidity Architecture. It delivers a highly capital-efficient mechanism for onchain RWA redemptions: committed capital can settle redemptions atomically without requiring pre-funded inventory or idle capital buffers, while remaining fully functional. The solution targets a broad range of Midas assets, including Fasanara’s mGLOBAL, recently launched on the Midas platform.
The model is straightforward. An asset manager submits a redemption request, and Symbiotic-registered market makers and curators respond with bids via an onchain RFQ system. The asset is priced, the best bid executes, and settlement occurs in a single transaction. Market makers do not need to pre-fund inventory and earn the spread on execution. The same system also supports lending market liquidations through Redstone Settle, addressing a frequent constraint in DeFi systems built around tokenized assets.
Symbiotic Core enables this capability. The upcoming V2 upgrade introduces capital facilities that allow assets in Symbiotic vaults to remain enforceable while being actively deployed between settlement events. Instead of sitting idle, committed capital can be allocated to whitelisted DeFi protocols like Morpho and Euler and automatically recalled when obligations trigger, enabling instant settlement without pre-funded liquidity. Additional partners involved include Keyring and Term Finance.
“Liquidity is what turns an asset class into a market. The RWA space has been building toward trillions without it. Symbiotic Core changes that: committed capital now functions as a liquidity sleeve, settling redemptions without sitting idle. This is what collateral markets infrastructure is built for.” – Misha Putiatin, Co-Founder, Symbiotic
Midas recently closed a $50 million Series A to build institutional-grade tokenized financial products. mGLOBAL is Fasanara’s flagship fund, tokenized on Midas and the first asset to go live on Symbiotic Instant Liquidity. Integrated within Midas’ Open Liquidity Architecture, this RFQ layer extends existing instant redemption capabilities with a fully onchain, capital-efficient settlement pathway available to qualified market makers.
“The biggest friction point for tokenized products has always been redemptions. You can put a fund onchain, but if exiting still takes several weeks, you haven’t really solved anything. Symbiotic Instant Liquidity, as part of Midas’ Open Liquidity Architecture, changes that equation. On top of that, the capital backing redemptions is productive until the moment it’s needed, then settles atomically.” – Dennis Dinkelmeyer, Co-Founder & CEO, Midas
Instant Liquidity is one offering within Symbiotic’s broader collateral markets ecosystem. Cap Labs, operating in credit, and Nexus Mutual, operating in insurance, are already live. Three different financial products, three different markets, one shared infrastructure.
Any issuer can integrate. Any market maker can participate.
About Symbiotic
Symbiotic powers collateral markets where capital is committed to financial obligations and enforced by code. Committed capital remains productive while still guaranteeing obligations, removing the trade-off between being locked and earning yield. Symbiotic backs products across credit, insurance, stablecoins, and real-world assets, powering 80+ vaults, over 74,000 active stakers, and 111 operators, with integrations such as Chainlink, Nexus Mutual, and Cap Labs live in production. Symbiotic is backed by Paradigm, Pantera, Cyber.fund and Coinbase Ventures.
symbiotic.fi
About Midas
Midas is a platform for composable onchain investment products that enables strategy managers to tokenize institutional strategies. Its “mTokens” offer investors transparency, instant redemption capabilities, and native composability across DeFi protocols such as Morpho and Pendle. Founded in 2024 by Dennis Dinkelmeyer (formerly Goldman Sachs), Fabrice Grinda (FJ Labs), and Romain Bourgois (formerly Ondo Finance), Midas is backed by investors including RRE, Creandum, Framework Ventures, HV Capital, Ledger Cathay and Coinbase Ventures. The company recently secured $50M in Series A funding and has supported over $1.7B in asset issuance and $37M in yield distributed to date.